SYRS News and Press, Syros Pharmaceuticals Inc. From 05/13/24

2024-05-13 12:10:49 ET More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript Syros jumps on FDA fast track tag for leukemia drug Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by $1.6M ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its firs...

2024-04-09 11:00:51 ET More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript Syros Pharmaceuticals: Rising Despite Dilution, A Must Look Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by $...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene in ...

2024-03-27 11:53:29 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Syros Pharmaceuticals (NASDAQ: SYRS ) just reported results for the fourth quarter of 2023. Syros Pharmaceuticals reported earnings per share of -$2.22. This was below the...

2024-03-27 10:40:24 ET Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Conference Call March 27, 2024, 08:30 AM ET Company Participants Karen Hunady - Director of IR and Corporate Communications Conley Chee - CEO David Roth - CMO Jason Haas - CFO Co...

2024-03-27 07:32:01 ET More on Syros Pharmaceuticals Syros Pharmaceuticals: Rising Despite Dilution, A Must Look Seeking Alpha’s Quant Rating on Syros Pharmaceuticals Historical earnings data for Syros Pharmaceuticals Financial information for Syros Ph...

-- Completed Enrollment of 190 Patients for Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial; Pivotal CR Data Expected by Mid-4Q 2024 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Also Expected in 2024 -- -- Completed a $45.0 Million Equity Offering, Extending Cash Runway into ...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

2024-03-26 13:53:14 ET More on Syros Pharmaceuticals Syros Pharmaceuticals: Rising Despite Dilution, A Must Look Seeking Alpha’s Quant Rating on Syros Pharmaceuticals Historical earnings data for Syros Pharmaceuticals Financial information for Syros Ph...